Oncology & Biotech News (OBTN) starts its fourth year of publication with a new look and an even stronger focus on bringing you the latest developments in clinical trial research, practice guidelines, and regulatory information.
Oncology & Biotech News
(OBTN) starts its fourth year of publication with a new look and an even stronger focus on bringing you the latest developments in clinical trial research, practice guidelines, and regulatory information. We are reaching out to more key opinion leaders and delivering their expert advice on topics relevant to physicians on the front line in the fight against cancer.
All year, we have listened to your input on what you need to improve your practice, and we will be incorporating your changes and suggestions as we go forward. In addition to improvements to the print publication, we are also expanding our online opportunities at www.ONClive.com, with daily features, blogs, and enhanced conference coverage.
Oncology & Biotech News
Part of our efforts to take to the next level includes enhancing our conference coverage, providing even more special supplements and live online reports. In 2010, our writers will be attending meetings held by AACR, ASCO, and ASH; the Chemotherapy Foundation Symposium; SABCS; and a number of smaller conferences, with the goal of making sure you do not miss a thing.
As always, I welcome your comments and suggestions. You can e-mail me through our editors any time, via firstname.lastname@example.org. It looks like 2010 is shaping up to be another banner year in oncology, and we are glad you will be spending it with us at OBTN.
This issue features important news on the National Comprehensive Cancer Center’s revisions to its guidelines for the management of early stage prostate cancer (p. 42). These revisions will be reviewed at the Third Annual Interdisciplinary Prostate Cancer Congress (IPCC), March 27, 2010, in New York City. I have been involved in every IPCC, which is sponsored by ArcMesa Educators, and it is definitely an invaluable program for medical professionals who treat prostate cancer. Registration is limited, and there are not a lot of slots remaining, so if you are interested in attending and plan to be in the New York area at that time, I would encourage you to register now. I cannot emphasize enough how helpful and enjoyable this program promises to be. The audience is given ample opportunity to participate in the discussion, which is case-based and pragmatic. You can read more about what will be covered at this year’s IPCC on page 10.